ERBB2 and neoplasm: Although MTSS1 was expressed in some HER2+ molecular subtypes, we observed its expression was markedly decreased in clinical tumour samples with the HER2+/ER−/PR− phenotype, suggesting hormonal androgen expression may mitigate for the loss of MTSS1 tumour suppressor functionality.